CNBC's Meg Tirrell reports the latest from Mylan CEO Heather Bresch's Congressional hearing on the rising price of the EpiPen.
Rep. Eleanor Norton (D-DC) questions Mylan CEO Heather Bresch about EpiPen pricing at her hearing on Capitol Hill.
Rep. John Mica (R-FL) questions Mylan CEO Heather Bresch about EpiPen compensation at her hearing on Capitol Hill.
Rep. Elijah Cummings (D-MD) questions Mylan CEO Heather Bresch about EpiPen program costs on Capitol Hill.
Mylan CEO Heather Bresch's testifies the rising price of the EpiPen on Capitol Hill and discusses EpiPen profits and program costs.
Mylan CEO Heather Bresch testifies about the EpiPen price hike on Capitol Hill.
Tobira Therapeutics shares surge after Allergan agrees to buy the drug developer for $1.7. CNBC's Meg Tirrell reports the details, as well as other biotech takeover targets surrounding progressive liver disease "NASH."
"Fast Money" trader Dan Nathan discusses unusual options activity in the biotech sector.
Ed Kaye, Sarepta Therapeutics interim CEO, speaks to CNBC's Meg Tirrell about what's next for the company following FDA's recent approval of muscular dystrophy drug eteplirsen.
CNBC's Meg Tirrell reports the latest of Gilead, including the company's $5 billion debt offering and Jefferies analysts saying a deal may be imminent.
Kevin Sharer, Harvard Business School, discusses competition in the pharmaceutical industry and balancing drug prices and profits.
Guggenheim Securities managing director Eric Wasserstrom weighs in on the big changes and next steps for Wells Fargo.
CNBC's Meg Tirrell takes a look at what may be ahead on the horizon for healthcare, with the likes of Obamacare and drug prices in the midst of the presidential campaign.
"Fast Money Halftime Report" trader Jon Najarian discusses unusual activity in biotech stock Novavax.
"Fast Money" trader Dan Nathan discusses why the S&P Biotech ETF (XBI) caught his eye.
Max Blankfeld, COO of FamilyTreeDNA.com, discusses the genetic testing industry, pricing and procedure.
The health care and technology conglomerate agreed to acquire Cepheid for $35 per share in cash.
Chris Raymond, Raymond James managing director and senior biotech analyst, shares his bullish take on Abbvie. The "Fast Money Halftime Report" traders and Barbara Doran, Yorkbridge director and senior portfolio manager, weigh in.
An inspection by the FDA uncovered problems with how the blood-testing startup collected patient data.
CNBC's Meg Tirrell reports that a House committee has sent a letter to Mylan for information on the EpiPen price increase.